Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients

NCT02551809 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL: UB-311
DRUG: Placebo

Sponsor

United Neuroscience Ltd.